ABSTRACT
BACKGROUND: Azithromycin has been considered as a possible therapeutic agent for COVID-19 patients. However, there is limited data on its efficacy. CASE PRESENTATION: We describe three patients diagnosed with COVID-19 who did not respond to the initial treatment but improved dramatically upon adding azithromycin with a successful outcome. CONCLUSION: We have presented evidence of the potential beneficial effect of the azithromycin in the treatment of patients with COVID-19 in three different clinical settings. More evidence is needed regarding the microbiological data, safety, and efficacy of this medication in the management of COVID-19.
Subject(s)
Azithromycin , COVID-19 Drug Treatment , Azithromycin/therapeutic use , Humans , Hydroxychloroquine , SARS-CoV-2ABSTRACT
BACKGROUND: In February 2020, coronavirus disease (COVID-19) emerged in Tehran, Iran. CASE PRESENTATION: Herein, we reported clinical features, laboratory tests, unusual radiological characteristics and therapeutic course of a patient with initial mild clinical symptoms at presentation with progression to pneumonia and pleural effusion in the emergency unit of a referral hospital.
